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1. Introduction 
Perophoramidine (1) and the family of alkaloids known as the 
communesins have provided a significant challenge to the 
synthesis community for more than a decade (Figure 1).1-5 Their 
complex polycyclic structures and the abundance of stereogenic 
centres, two of them being all carbon quaternary centres, have 
tested a range of synthetic methodologies to the full. We have 
reported a total synthesis of the simplified 
dehaloperophoramidine (2) structure which involved, as a key 
carbon-carbon bond forming step, the Lewis-acid catalysed 
opening of epoxides of the general type 3 and subsequent 
trapping with allyl-trimethylsilane to give 4.6,7 This strategy was 
inspired by a series of observations on structurally related cyclic 
ethers. The synthesis and studies on the reactivity of these 
previously unreported ethers are described here. 
Figure 1: Structures of Perophoramidine (1), the related Dehaloperophoramidine (2) and 
a key step in our previously reported synthesis of 2. Reaction conditions: a) Allyl-TMS 
(2.5 eq.), TiCl4 (4 eq.), CH2Cl2, -78 oC see refs. 6 and 7 for more details. 
 
Scheme 1: Synthesis and subsequent reaction of cyclic ether 6; Reagents and conditions: 
a) AlCl3 (7 eq.), CH2Cl2, rt, 95%; b) AlCl3 (7 eq.), CH2Cl2, rt then after work up AlCl3 (7 
eq.), PhMe, rt, 46% over 2 steps. The structures of 6 (left) and 7 (in box) were confirmed 
by X-ray crystallographic analysis. 
2. Results and Discussion 
Our interest in cyclic ethers in this context was first aroused 
when allylic alcohol 5 was treated with an excess of aluminium 
trichloride at room temperature in dichloromethane. In line with 
previous literature precedent using AlCl38 and work using 
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The bioactive alkaloid natural product perophoramidine and the related family of compounds 
known as the communesins have inspired the synthesis community for more than a decade. 
Many of the elegant approaches have required the synthesis of complex intermediates that have 
not always reacted in the expected manner. In this study we describe a series of cyclic ether-
containing precursors that were prepared during our synthetic studies towards these natural 
products. Attempts to open the cyclic ether ring and trap the resulting stabilised carbocation with 
a carbon nucleophile ultimately led to the preparation of a diallyl-substituted all carbon 
quaternary centre.  Subsequent attempts to differentiate between the two allyl groups resulted in 
a relatively clean transformation to an unexpected compound. Extensive structural 
characterisation, including small molecule X-ray crystallography, showed that a dearomatisation 
reaction had occurred. 
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BF3.Et2O,9 both on unrelated structures, we observed highly 
diastereoselective formation of cyclic ether 6 in 95% yield 
(Schemes 1 and S1). Small molecule X-ray crystallographic 
analysis of 6 confirmed the structure as drawn. A limited screen 
of alternative Lewis acids (Table S1) suggested that the use of 
AlCl3 was important for the formation of 6 from 5. Interestingly, 
when toluene was used as a solvent in place of dichloromethane 
in the AlCl3 reaction, a second product assigned as structure 7, 
resulted from ring opening of the cyclic ether ring. The 1H NMR 
of 7 was noteworthy due to the presence of an apparent doublet 
(with a small coupling constant of J = 1.3 Hz) equating to 4 
protons in the aromatic region. Combined with the presence of a 
new signal corresponding to an aromatic methyl group and other 
analytical data, it was concluded that a molecule of the solvent 
(toluene) had been incorporated into the product during this 
reaction. Small molecule X-ray crystallographic analysis of 7 
confirmed the structure and the observed signal in the 1H NMR 
spectrum of 7 was rationalised based on a small chemical shift 
difference between the aromatic protons in the toluene ring in 7 
leading to a small coupling constant. Exposure of a crude sample 
of 6 prepared in dichloromethane to excess AlCl3 in toluene gave 
exclusively 7 as a single diastereomer (Scheme S1). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2: 5-membered cyclic ethers 12 were viewed as a central unit in a plan to form 
an all-carbon quaternary centre at position C11 in 11. a) Conversion of previously 
reported aldehyde 8 to ethers 9 and 10. Reaction conditions: a TBAF, p-TsCl, DMAP, 
CH2Cl2, rt, 82%; b (i) NaClO2, NaH2PO4, 2-methylbut-2-ene, tBuOH, H2O, rt, 2h; (ii) 
TMSCHN2, MeOH, rt, 1h, 54% over two steps. b) proposed route from 13 via cyclic 
ethers of general structure 12  to 11 inspired by the experimental observations shown in 
Schemes 1 and 2a. 
A second interesting observation came following our previously 
reported synthesis of the α-hydroxy aldehyde 8 (Scheme 2a).7 
Reaction of 8 with TBAF in the presence of tosyl chloride and 
DMAP resulted in the formation of another 5-membered cyclic 
ether 9 (Scheme S2 for a more detailed discussion). In contrast to 
cyclic ether 6 (Scheme 1), ether 9 does not possess a hydrogen 
atom at the C11 position. The conversion of 8 to 9 was assumed 
to occur via tosylation of the initial formed primary alkoxide 
followed by nucleophilic substitution involving attack of the 
tertiary alcohol/alkoxide at the tosyl-substituted carbon. 
Subsequent oxidation of aldehyde 9 and esterification gave cyclic 
ether 10 in moderate yield over the two steps. Combining the two 
observations described in Schemes 1 and 2a led us to consider a 
new approach for establishing the C11 all carbon quaternary 
centre in compounds of general type 11 (Scheme 2b). This 
strategy would involve the synthesis of relevant C11-substituted 
cyclic ethers of the general type 12 which could potentially 
undergo ring opening and trapping with a suitable carbon 
nucleophile. The conversion of the ketone 13 to 12 became the 
next challenge. 
Rapid access to the C11-H cyclic ether 14 was achieved 
following reduction of 13 using sodium borohydride to give 15. 
Reaction of 15 with tosyl chloride in pyridine (2 hours at room 
temperature 
 followed by heating at 60 oC), inspired by existing literature on 
unrelated structures,10 gave 14. Cyclic ethers 16-18 were 
prepared in excellent yields and as single diastereomers by an 
analogous route using greater than two equivalents of the 
corresponding Grignard reagent to give alcohols 19-21. 
Cyclisation of 19-21 using tosyl chloride gave 16-18. Finally, 
increased quantities of cyclic ether 10 were prepared from 13 via 
O-silylation to give 22, diastereoselective conversion to the 
epoxide 23 followed by deprotection to give 24. Reaction of 
epoxide 24 with p-toluenesulfonic acid11 at room temperature 
gave the cyclic ether 25 in excellent yield. Dess-Martin 
oxidation12 of 25 to 9 followed by Pinnick oxidation13 and 
esterification gave 10. 
 
Scheme 3: Formation of cyclic ethers 14, 16-18, 25, 9 and 10. Reaction conditions: a 
NaBH4, MeOH, 0 oC to rt, 1h 95% for 15; b MeMgCl (2.2 eq.), THF, 0 oC to rt, 1h, 98% 
for 19; c EtMgCl (4 eq.), THF, 0 oC to rt, 1h, 96% for 20; d allyl MgCl (3.0 eq.), THF, 0 
oC to rt, 1h, 92% for 21; e p-TsCl, pyridine, rt, 2hs then 60 oC for 5 hs., 70% for 14, 81% 
for 16, 84% for 17, 70% for 18; f TPDBS-Cl, imid., DCM, rt, 1 h; g; ClICH2, 
MeLi:LiBr, THF, 6 h, -78 oC – rt, 71% (2 steps); h TBAF, THF rt, 2 hs, 98%; i p-TsOH, 
CH2Cl2, rt, 18hs, 94%; j Dess-Martin periodinane,12 CH2Cl2, rt, 1h, 90%; k (i) NaClO2, 
NaH2PO4, 2-methylbut-2-ene, tBuOH, H2O, rt, 2h; (ii) TMSCHN2, MeOH, rt, 1h, 54% (2 
steps). 
 
Having accessed a number of cyclic ethers of general structure 12 
(Scheme 2b), attempts to open the ether ring with concomitant 
trapping of the resulting carbocation with a carbon nucleophile 
were carried out. Initially we returned to the AlCl3-mediated 
opening in toluene. Encouragingly, cyclic ethers 14, 16 and 17 
were converted under these conditions to 26, 27 and 28 
respectively (Figure 2) in an analogous manner to the conversion 
of 6 to 7 (Scheme 1). Evidence to support the assigned relative 
stereochemistry of 26-28 came from NOESY experiments 
(Figures S1-S3). It was determined that greater than 3 eqs. of 
AlCl3 were required for these reactions to proceed possibly due to 
competing coordination of the Lewis acid to other heteroatoms. 
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Figure 2: Structures of compounds obtained from ring opening of cyclic ethers followed 
by trapping with a carbon-based nucleophile. Reagents and conditions: AlCl3 (7 eq.), 
PhMe, rt, 77% for 26 from 14; 83% for 27 from 16; 70% for 28 from 17. AlCl3 (7 eq.), 
allylTMS (10 eq.), CH2Cl2, rt, 1h. 87% for 29 from 16; 68% for 30 from 17; TiCl4 (5 
eq.), allylTMS (5 eq.), CH2Cl2, -78 oC, 4.5hs. 87% for 31 from 18. 
 
The reaction of cyclic ether 18 (Scheme 3) with AlCl3 in toluene 
led to full consumption of the starting material but a complex 
mixture of products was formed and the expected product could 
not be isolated. Unfortunately, cyclic ethers 10 and, perhaps more 
surprisingly, 25 did not react at room temperature even after 
extended reaction times (up to 18 hours). Increasing the number 
of equivalents of AlCl3 and/or heating the reaction using 
conventional or microwave methods had no effect. Use of a p-
toluenesulfonic acid-mediated protocol, that had been successful 
for the conversion of 14 to 26, did not work in the case of 25 
(Scheme S3) Use of the Hosomi-Sakuri protocol14 with AlCl3 and 
allyltrimethylsilane as the nucleophile in dichloromethane 
enabled the synthesis of 29 and 30 from 16 and 17 respectively 
(Figures 2, S4 and S5). Again, the attempted reaction of 18 gave 
a complex mixture and, despite considerable efforts (Table S2), 
none of the desired products could be obtained when 10 and 25 
were used under these conditions. However a change of Lewis 
acid from AlCl3 to TiCl4, inspired by a report from Heathcock,15 
did enable the synthesis of 31 (Figure 2) from 18 in 87% yield. 
Having successfully established a robust route to an all carbon 
quaternary centre at C11 in 31, it became clear that to progress 
further towards the natural products it would be necessary to 
differentiate between the two allyl groups present at the C11 
position. One possible approach to this was to attempt a selective 
iodoetherification reaction on 31 in the hope that a 7-membered 
cyclic ether ring (as in 32, Scheme 4) would form on reaction of 
the primary alcohol in 31 with the allyl group that was on the 
same face (as opposed to the other more distant C11-allyl group). 
The remainder of this report describes the unexpected outcome of 
the attempted iodoetherification reaction of 31. 
 
 
Scheme 4: The attempted conversion of 31 to 32. Reagents and conditions: a NIS (1.2 
eqs.), CH2Cl2, rt, 1h, 40% recovered starting material 31; 15% of 33 and 9% of 34. See 
Figure 3 and Scheme 5 for the structures of 33 and 34. The use of the A and the D-ring 
nomenclature is highlighted in the structure of the starting material 31. 
 
Preliminary studies on the reaction of 31 with iodine or N-
iodosuccinimde (NIS) in a range of solvents including 
acetonitrile and dichloromethane, with or without the addition of 
base (NaHCO3 or NaHMDS), resulted in the partial reaction of 
31 to give on all occasions what appeared to be a mixture of 3 
major products along with some unreacted starting material 31. It 
proved possible to isolate 2 of the new products (33 and 34) in 
sufficient quantities for detailed analysis. 1H NMR analysis of the 
first of these products indicated that only one allyl group was still 
present (Figure 3a, red section in structure). It was also clear that 
the C-10b CH2-CH2-O substituent present in 31 was retained, but 
that the signals corresponding to the CH2-O group had shifted 
from 2.85 and 3.11 ppm in 31 to 3.65 and 3.99 ppm (Figures 3a 
and S6). The significant downfield shift of these types of signals 
had been observed on several occasions during this work 
following cyclic ether formation. A new singlet at 4.27 ppm 
corresponding to a CH proton was also observed, with the proton 
being bonded to a carbon atom with a 13C NMR chemical shift of 
88.0 ppm (data not shown). This peak was not present in the 
starting material 31 and would not be expected in 32. There was 
also (i) a CH2I group (as observed by a characteristic 13C peak at 
9.0 ppm), (ii) an additional CH2 group and (iii) a CH (observed 
as a multiplet at around 2.4 ppm) bonded to a carbon atom with a 
13C chemical shift of 45.7 ppm. Analysis of the COSY spectrum 
indicated that the CH multiplet at 2.4 ppm correlated with both 
the CH2I and the other CH2 group. This suggested that the atoms 
corresponding to these signals were connected in the sequence 
CH2I-CH-CH2 with this fragment most likely coming from the 
reaction of one of the allyl substituents with iodine. The CH 
proton did not correlate with any other signal (Figure 3 blue 
section in structure). The aromatic region of the 1H NMR 
spectrum contained only 10 protons with 8 CH environments 
observed in the HSQC spectrum. This was lower than the 13 
aromatic protons present in the starting material 31 and the 
expected product 32, suggesting that some change to the 
molecule had taken place in one or more of the aromatic rings. 
 
 
Figure 3: The attempted conversion of 31 to 32. Reagents and conditions: a NIS (1.2 
eqs.), CH2Cl2, rt, 1h, 40% recovered starting material 31; 15% of 33 and 9% of 34. See 
above and Figure 4 for the structures of 33 and 34. 
 
Analysis of the 13C NMR spectrum indicated that there were 30 
carbon atoms present in the product, suggesting that no carbon 
atoms were lost or gained in the reaction. DEPTQ analysis 
identified a CH signal with a chemical shift of 146.5 ppm, which 
was much higher than any CH carbon observed in related 
compounds. It was thought that this signal may have originated 
from the A ring of 31. It was also noted that the signals 
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31 were not observed (Scheme 4), suggesting that reaction had 
taken place on this ring. There also appeared to be 7 CH2 carbon 
environments present and 10 quaternary carbon environments. 
This was 2 more quaternary carbons than in 31 or would be 
expected in 32. With this information in mind, the HMBC 
spectrum of the product was analysed to try to determine the 
atom connectivity. The CH singlet at 4.27 ppm correlated with 
seven other carbon atoms (Figure 3) including a CH2O (67.2 
ppm), CH (45.7 ppm) and a CH (146.5 ppm). These correlations 
suggested that this CH group was within 2-3 bonds of the C-10b 
substituent, the signals corresponding to the reacted allyl and the 
A ring. The close bonding proximity of all of these groups, and 
the large number of HMBC correlations observed for this CH 
singlet suggested that a multi-ring system may have been formed. 
Surprisingly, it seemed likely that the A ring was no longer 
aromatic and now contained four quaternary carbons. High 
resolution mass spectrometric analysis of the product found a m/z 
of 812.9329, which was much higher than that of the starting 
material 31 (435.2430 [M+H]+) and the expected product 32 
(561.1403, expected [M+H]+). This mass corresponded to a 
molecular formula of C30H28O1N2I3 which suggested the addition 
of 3 iodine atoms and the loss of three hydrogen atoms had 
occurred relative to 31. This data, as well as that obtained from 
the NMR analysis, led to the proposal that this product was 33 
(Figure 3, Scheme 5 and Tables S3 and S4 for full assignments of 
1H and 13C NMR). This proposed structure of 33 was found to be 
consistent with all of the characterisation data obtained including 
the key HMBC correlations.  
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Scheme 5: Optimised formation of 33 from 31. Reagents and conditions: a NIS (3.6 eq), 
CH2Cl2, rt, 6 h, 65%. One possible mechanism for the reaction is shown. The structure of 
33 was confirmed by X-ray crystallographic analysis. 
 
The unusual structure proposed for 33 contained three contiguous 
all carbon quaternary carbon centres, as well as two additional 
stereocentres. It was thought that at least 3 equivalents of NIS 
were required to produce 33 and so the reaction of 31 was 
repeated with 3.6 equivalents of NIS resulting in the production 
of 33 as a single product in reasonably high yield (65%). Upon 
recrystallisation of 33 from ethyl acetate and methanol, a crystal 
was obtained that was suitable for X-ray crystallographic 
analysis. The analysis found a pair of enantiomers present in the 
unit cell in line with the fact that the starting material 31 was 
racemic. This analysis confirmed that the connectivity in the 
structure of 33 was as assigned by NMR and mass spectrometric 
analysis and enabled the relative stereochemistry of 33 to be 
assigned (Scheme 5). One possible mechanism for the formation 
of 33 could involve reversible reaction of 31 with NIS to form a 
series of iodonium ions, one of which (35 in Scheme 5) could 
undergo nucleophilic attack from the aromatic A ring to give 36. 
This would lead to formation of a new ring by linking one of the 
two allyl substituents and the C-10a position. The alcohol 
substituent could then add to the extended iminium system in 36 
to form the cyclic ether ring. Subsequent iodination of the diene 
unit by the remaining NIS could form 33. Evidence to support 
this mechanism came from the observation that the second 
product from the original studies was assigned the structure 34 
based on comparison of the NMR analysis with that of 33. The 
three signals corresponding to the diene protons in 34 were all 
found in the 5.6 – 6.4 ppm region of the 1H NMR spectrum 
(Figure S7), as expected. Treatment of a crude sample of 34 with 
NIS led to formation of 33 (Figure S8). 
 
3. Conclusions 
      In conclusion, we have described the synthesis of a series of 
cyclic ether containing compounds that are structurally related to 
the bioactive alkaloid natural product perophoramidine (1). 
Attempts to open the ether rings and trap the resulting 
carbocations with carbon nucleophiles proved successful in 
several cases leading us to the C11-diallylated compound 31. In 
order to progress further towards the target molecules 1 and 2, an 
attempt was made to differentiate between the two allyl 
substitutents using an intramolecular iodoetherification protocol. 
Unexpectedly, this led to a major structural change involving an 
unusual dearomatisation reaction. The hexacyclic core structure 
that results contains 3 contiguous all carbon quaternary centres 
and five stereogenic centres in total. To the best of our 
knowledge, the closest literature precedent (Scheme S4) proceeds 
via radical intermediates rather than likely carbocation 
intermediates involved in the chemistry described here.16 We 
remain surprised by the complexity of the compounds formed 
during, what appeared on paper at least, to be a reasonable 
synthetic plan. 
4. Experimental 
4.1. General methods 
 
All chemicals and solvents were purchased from Sigma Aldrich 
(UK) or Alfa-Aesar and used without further purification.  All 
reactions were carried out under a positive pressure of nitrogen or 
argon in flame or oven-dried glassware. Thin layer 
chromatography (TLC) analysis was performed on silica pre-
coated SIL G-25 UV254 sheets (layer: 0.25 mm silica gel with 
fluorescent indicator UV254, Alugram, UK).  Compounds were 
visualised by UV light (UV lamp, model UVGL-58, Mineralight 
LAMP, Multiband UV-254/365 nm) and stained with potassium 
permanganate.  Flash column chromatography was carried out on 
silica gel (40-63 µm, Fluorochem, UK). Melting points were 
measured with an Electrothermal 9100 capillary melting point 
apparatus and are uncorrected. Fourier Transform infra-red 
spectra (FT-IR) were acquired on a Perkin Elmer paragon 1000 
FT spectrometer.  Absorption maxima are reported in 
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wavenumbers (cm -1). Unless otherwise stated, 1H and 13C NMR 
spectra were measured at room temperature (298 K) on a Bruker 
DPX 400 (1H = 400 MHz, 13C = 100 MHz); Bruker Avance 300 
(1H = 300 MHz, 13C = 75 MHz) and a Bruker Avance 500 
(1H = 500.1 MHz, 13C = 125 MHz).  Deuterated solvents were 
used and 1H NMR chemical shifts were internally referenced to 
CHCl3 (7.26 ppm) in chloroform-d1 solution. Chemical shifts are 
expressed as δ in unit of ppm and coupling constants are recorded 
in Hz. Data processing was carried out using TOPSPIN 2 NMR 
version (Bruker UK, Ltd) or MestreNova 9.0 program (Bruker 
UK Ltd). In 1H NMR assignment the multiplicity used is 
indicated by the following abbreviations:  s = singlet, d = 
doublet, dd = doublet of doublets, t = triplet, q = quartet, m = 
multiplet, brs = broad singlet.  Signals of protons and carbons 
were assigned, as far as possible, by using the following two-
dimensional NMR spectroscopy techniques:  [1H-1H] COSY, 
[1H-13C] HSQC (Heteronuclear Single Quantum Coherence) and 
long range [1H-13C] HMBC (Heteronuclear Multiple Bond 
Connectivity). Mass spectrometry analysis (electrospray mode, 
ES; chemical ionization mode, CI) were performed by Ms 
Caroline Hosburgh and were recorded on a high performance 
orthogonal acceleration reflecting TOF mass spectrometer 
operating in positive and negative mode, coupled to a Waters 
2975 HPLC. 
 
 
4.2. General Procedures 
 
4.2.1. Aluminum trichloride-mediated opening of cyclic ether 
compounds in touene 
 
To a solution of the cyclic ether compound (1 eq.) in toluene (1 
vol) was added AlCl3 (7 eq.). The mixture was stirred at rt for 1h 
before 1M NaOH (1 vol) was added and the mixture extracted 
with ethyl acetate (3 x 1 vol). The organic extracts were dried 
(MgSO4), filtered and concentrated before purification by column 
chromatography (EtOAc/hexanes) to give the desired product. 
 
4.2.2. Aluminum trichloride-mediated opening of cyclic ether 
compounds in the presence of allyltrimethyl silane. 
 
To a solution of the cyclic ether compound (1eq.) in DCM (1 vol) 
was added allyltrimethylsilane (10 eq.) followed by AlCl3 (7 eq.). 
The mixture was stirred at rt for 1h before 1M NaOH (10 vol) 
was added and the mixture extracted with DCM (3 x 10 vol). The 
combined organic extracts were dried (MgSO4), filtered and 
concentrated before the crude product was purified by column 
chromatography (EtOAc/hexanes) to give the alcohol product. 
 
4.3. Compounds synthesised 
 
4.3.1. (±)-(2R,10bS,11S)-5-benzyl-2'-methyl-1',2',10b,11-
tetrahydrofuro[3,2-c]indolo[2,3-b]quinoline (6) 
 
To a stirred solution of 57 (0.05 g, 0.137 mmol) in CH2Cl2 (10 
mL) was added AlCl3 (0.131 g, 0.985 mmol). The suspension 
was stirred at rt for 18h before sat. aq. NaHCO3 (10 mL) was 
added to quench the reaction. The aqueous layer was separated 
and extracted with CH2Cl2 (2 x 10 mL) and the combined organic 
extracts were washed with water (20 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by column chromatography 
on silica gel (20% EtOAc/hexane) afforded 6 (0.048 g, 0.133 
mmol, 95%). Crystals suitable for X-ray analysis were obtained. 
I.R. (ATR) νmax: 1555, 1456, 1045, 999, 802 cm-1; 1H NMR (300 
MHz, CDCl3) δ 7.66 (1H, ddd, J=7.5, 1.5, 1.0 Hz), 7.50 – 7.44 
(2H, m), 7.38 – 7.30 (5H, m), 7.30 – 7.24 (1H, m), 7.24 – 7.17 
(1H, m), 7.15 – 7.07 (2H, m), 6.96 (1H, dd, J=8.0, 1.0 Hz), 5.96 
(1H, d, J=16.5 Hz), 5.27 (1H, s), 5.10 (1H, d, J=16.5 Hz), 4.74 
(1H, qd, J=9.5, 6.0 Hz), 2.31 – 2.23 (1H, m), 2.12 (1H, dd, 
J=12.0, 6.5, 0.5 Hz), 1.19 (3H, d, J=6.0 Hz); 13C NMR (75 MHz, 
CDCl3) δ 171.7, 154.4, 139.7, 138.1, 137.0, 129.7, 129.1, 129.0, 
128.7, 127.4, 126.5, 126.0, 122.9, 122.7, 121.6, 118.0, 115.0, 
79.2, 75.1, 58.3, 49.3, 44.3, 22.9; LRMS (ESI) m/z 367 ([M+H]+, 
100), 389 ([M+Na]+, 60); HRMS (ESI) m/z [M+H]+ calcd. for 
C25H23N2O+ 367.1805, found 367.1794. 
 
4.3.2. (±)-1-((10bS,11R)-5-benzyl-11-(p-tolyl)-5,11-dihydro-
10bH-indolo[2,3-b]quinolin-10b-yl)propan-2-ol (7) 
 
To a stirred solution of 5 (0.05 g, 0.137 mmol) in PhMe (10 mL) 
was added AlCl3 (0.131 g, 0.985 mmol). The suspension was 
stirred at rt for 18h before sat. aq. NaHCO3 (10 mL) was added to 
quench the reaction. The aqueous layer was separated and 
extracted with EtOAc (2 x 10 mL) and the combined organic 
extracts were washed with water (20 mL), dried (MgSO4) and 
concentrated in vacuo.  Purification by column chromatography 
on silica gel (EtOAc/hexane) afforded 7 (0.029 g, 0.063 mmol, 
45%). Crystals suitable for X-ray analysis were obtained. I.R. 
(ATR) νmax: 3250, 1558, 1541, 1456, 1215, 1140 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.49 – 7.42 (2H, m), 7.38 (2H, dd, J=8.0, 
7.0 Hz), 7.36 – 7.26 (2H, m), 7.24 – 7.13 (3H, m), 7.13 (1H, ddd, 
J=7.5, 1.0 Hz), 7.08 (1H, d, J=8.0 Hz), 7.02 – 6.89 (2H, m), 6.79 
(4H, d, J=1.5 Hz), 5.98 (1H, d, J=16.0 Hz), 5.06 (1H, d, J=16.5 
Hz), 4.60 (1H, s), 3.71 – 3.62 (1H, m), 2.29 – 2.10 (2H, m), 2.11 
(3H, d, J=1.0 Hz), 0.99 (3H, dd, J=6.5, 1.0 Hz); 13C NMR (101 
MHz, CDCl3) δ 173.0, 155.5, 140.0, 137.3, 136.4, 136.4, 136.3, 
130.8, 128.9, 128.6, 128.3, 127.9, 127.6, 127.0, 126.4, 123.5, 
123.5, 122.2, 118.1, 115.4, 65.5, 57.0, 50.9, 49.7, 45.9, 24.2, 
21.0; LRMS (ESI) m/z 459 ([M+H]+, 100), 481 ([M+Na]+, 100); 
HRMS (ESI) m/z [M+H]+ calcd. for C32H31N2O+ 459.2431, found 
459.2417. 
6 (0.016 g, 0.044 mmol, 31%) was also isolated from this 
reaction. An alternative protocol for the preparation of 7 was also 
used: To a stirred solution of 5 (0.04 g, 0.109 mmol) in CH2Cl2 
(2 mL) was added AlCl3 (0.102 g, 0.765 mmol). The suspension 
was stirred at rt for 18h before sat. aq. NaHCO3 (5 mL) was 
added to quench the reaction. The aqueous layer was separated 
and extracted with CH2Cl2 (2 x 10 mL) and the combined organic 
extracts were washed with water (10 mL), dried (MgSO4) and 
concentrated in vacuo to afford 6 which was used without further 
purification. To a stirred solution of 6 (0.109 mmol) in PhMe (3 
mL) was added AlCl3 (0.106 g, 0.797 mmol). The suspension 
was stirred at rt for 18h before sat. aq. NaHCO3 (5 mL) was 
added to quench the reaction. The aqueous layer was separated 
and extracted with CH2Cl2 (2 x 10 mL) and the combined organic 
extracts were washed with water (10 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by column chromatography 
on silica gel (EtOAc/hexane) afforded 7 (0.023 g, 0.05 mmol, 
46%, 2 steps). 
 
4.3.3. (±)-(3aR,13bR)-9-Benzyl-2,3,9,13b-tetrahydrofuro[3,2-
c]indolo[2,3-b]quinoline-13b-carbaldehyde (9)  
 
To a solution of 87 (45 mg, 0.071 mmol) in DCM (1 mL) was 
added p-toluenesulfonyl chloride (20 mg, 0.106 mmol), 4-
dimethylaminopyridine (15 mg, 0.120 mmol) and tetra-n-
butylammonium fluoride (2M in THF, 70 µL, 0.141 mmol). The 
mixture was stirred at room temperature for 2h before NH4Cl 
(aq.) (3 mL) was added and the mixture extracted with DCM (3 x 
3 mL). The combined organic extracts were dried (MgSO4), 
filtered and concentrated to give the crude product. Purification 
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an orange-brown solid (22 mg, 82%).  
m.p. 82-85 °C; I.R. (KBr) νmax: 2921, 1732, 1558, 1453, 1206, 
754, 732 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.43 (s, 1H), 7.36 
(d, J = 7.5 Hz, 1H), 7.33 (d, J = 7.5 Hz, 1H), 7.30 – 7.12 (m, 9H), 
6.98 (t, J = 7.5 Hz, 1H), 6.89 (d, J = 8.5 Hz, 1H), 5.66 (d, J = 
16.5 Hz, 1H), 5.17 (d, J = 16.5 Hz, 1H), 4.41 (q, J = 8.5 Hz, 1H), 
4.08 – 4.01 (m, 1H), 2.67 (dt, J = 12.0, 9.5 Hz, 1H), 2.13 – 2.05 
(dt, J = 12.0, 9.7 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 196.0, 
170.1, 154.3, 139.7, 136.3, 135.9, 130.4, 129.2, 128.9, 128.2, 
127.4, 126.4, 123.3, 123.1, 122.0, 121.6, 118.5, 115.6, 89.6, 66.0, 
57.7, 49.1, 37.5; HR MS [ES+]: m/z calcd. for C25H21N2O2 
381.1603, found 381.1596 [M+H]+. 
Compound 9 was also prepared as follows: To a solution of 25 ( 
50 mg, 0.131 mmol) in DCM (1.5 mL) was added Dess-Martin 
periodinane (67 mg, 0.158 mmol) and the mixture stirred at rt for 
1h. Na2S2O3 (aq.) (2 mL) and NaHCO3 (aq.) (2 mL) were added 
and the mixture was stirred for a further 30 minutes before being 
extracted with DCM (3 x 5 mL). The combined organic extracts 
were dried (MgSO4) filtered and concentrated before purification 
by column chromatography (EtOAc/hexanes) to give 9 as an 
orange-brown solid (45 mg, 90%). All characterisation data were 
as reported above. 
 
4.3.4. (±)-rac-(3aS,13bS–Methyl 9–benzyl-2,3,9,13b–tetra-
hydrofuro[3,2-c]indolo[2,3-b]quinoline-13b-carboxylate (10) 
 
To a solution of 9 (40 mg, 0.105 mmol) in tBuOH : H2O (1:1, 2 
mL) was added 2-methylbut-2-ene (0.11 mL, 0.210 mmol), 
NaH2PO4 (213 mg, 1.367 mmol) and sodium chlorite (124 mg, 
1.367 mmol). The mixture was stirred at rt for 2h before water (5 
mL) was added and the mixture extracted with EtOAc (4 x 5 
mL). The combined organic extracts were dried (MgSO4), 
filtered and concentrated in vacuo to give the crude acid product. 
The crude was redissolved in anhydrous methanol (2 mL) and 
(trimethyl-silyl)diazomethane (2M in diethyl ether, 105 µL, 
0.210 mmol) was added. The solution was stirred for 1h at rt 
before acetic acid was added (50 µL) and the mixture stirred for a 
further 0.5h. NaHCO3 (aq.) (5 mL) was added and the mixture 
extracted with DCM (4 x 5 mL) before the combined organic 
extracts were dried (MgSO4), filtered and concentrated in vacuo 
to give the crude ester. Purification by column chromatography 
(10-20% Ethyl acetate/hexanes) gave 10 as a pale orange solid 
(23 mg, 54%). 
m.p. 69-71 °C; I.R. (KBr) νmax: 2950, 1764, 1722, 1557, 1491, 
1468, 1451, 1204, 1101, 757 cm-1; 1H NMR (300 MHz, CDCl3) δ 
7.59 (dd, J = 7.5, 1.5 Hz, 1H), 7.41 – 7.19 (m, 9H), 7.08 – 7.00 
(m, 2H), 6.97 (d, J = 8.0 Hz, 1H), 5.64 (d, J = 16.5 Hz, 1H), 5.42 
(d, J = 16.5 Hz, 1H), 4.43 (q, J = 8.5 Hz, 1H), 4.02 (ddd, J = 
10.0, 8.5, 3.0 Hz, 1H), 3.33 (s, 3H), 2.69 (dt, J = 12.5, 10.0 Hz, 
1H), 2.15 (ddd, J = 12.0, 8.0, 3.0 Hz, 1H); 13C NMR (75 MHz, 
CDCl3) δ 171.0, 168.5, 153.7, 138.9, 137.0, 136.3, 130.2, 129.0, 
128.8, 127.4, 127.4, 126.6, 123.3, 123.2, 123.0, 121.4, 117.9, 
115.6, 86.6, 65.5, 58.0, 52.4, 49.0, 37.0; HRMS [ES+]: m/z calcd. 
for C26H23N2O3 411.1703, found 411.1704 [M+H]+. 
 
4.3.5. (±)-(10bR,11R)-5-Benzyl-10b-(2-hydroxyethyl)-10b,11-
dihydro-5H-indolo[2,3-b]quinolin-11-ol (15) 
 
To a solution of 137 (1.00 g, 2.71 mmol) in MeOH (30 mL) at 0 
°C was added NaBH4 (0.21 g, 5.42 mmol). The mixture was 
stirred at 0 °C for 5 minutes before removing the ice-bath and 
allowing the mixture to stir at rt for a further 1h. NH4Cl (aq.) (30 
ml) was added and the organic solvent was removed under 
reduced pressure before the mixture extracted with DCM (3 x 30 
ml). The combined organic extracts were dried (MgSO4), filtered 
and concentrated to give the crude product. The crude product 
was purified by column chromatography (EtOAc/hexanes) to 
give 15 as a white solid (0.98 g, 97%). m.p. 180-181 °C; I.R. 
(KBr) νmax: 3320, 2143, 1555, 1469, 1452, 1206, 1059, 761, 702 
cm
-1
. 
1H NMR (500 MHz, CDCl3) δ 7.67 – 7.57 (m, 2H), 7.39 – 
7.16 (m, 8H), 7.13 – 7.04 (m, 2H), 6.90 (d, J = 8.0 Hz, 1H), 5.75 
(d, J = 16.5 Hz, 1H), 4.97 (d, J = 16.5 Hz, 1H), 4.89 (s, 1H), 3.70 
(t, J = 9.5 Hz, 1H), 3.54 (t, J = 10.0 Hz, 1H), 2.39 (s, 1H), 2.34 – 
2.26 (m, 1H), 1.75 – 1.46 (m, 1H). 13C NMR (126 MHz, CDCl3) 
δ 174.7, 155.6, 138.9, 136.7, 128.8, 128.8, 128.5, 127.5, 127.3, 
126.3, 125.5, 124.2, 123.4, 122.4, 117.8, 114.8, 70.9, 58.9, 56.0, 
49.7, 32.8. HRMS [ES-]: m/z calcd. for C24H21N2O2 369.1603, 
found 369.1603 [M-H]-. 
 
4.3.6. (±)-(3aR,13bR)-9-Benzyl-2,3,9,13b-tetrahydrofuro[3,2-
c]indolo[2,3-b]quinoline (14) 
 
To a solution of 15 (100 mg, 0.270 mmol) in pyridine (5 mL) 
was added p-toluenesulfonyl chloride (57 mg, 0.297 mmol) and 
the solution stirred at rt for 2h. The mixture was then heated to 60 
°C for a further 5h before cooling to rt and adding 1M HCl (75 
mL). The mixture was extracted with DCM (3 x 30 mL) and the 
combined organic extracts were dried (MgSO4), filtered and 
concentrated to give the crude product. Purification by column 
chromatography (EtOAc/hexanes) gave 14 as a pale yellow solid 
(67 mg, 70%). m.p. 122- 124 °C; I.R. (KBr) νmax: 2921, 1737, 
1555, 1464, 1199, 754 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.52 
(dd, J = 7.5, 1.0 Hz, 1H), 7.38 (d, J = 7.5 Hz, 1H), 7.34 (d, J = 
7.5 Hz, 1H), 7.30 – 7.16 (m, 6H), 7.13 (t, J = 7.5 Hz, 1H), 7.05 – 
6.98 (m, 2H), 6.86 (d, J = 8.5 Hz, 1H), 5.85 (d, J = 16.5 Hz, 1H), 
5.26 (s, 1H), 4.97 (d, J = 16.5 Hz, 1H), 4.22 (q, J = 8.5 Hz, 1H), 
3.91 (td, J = 10.0, 9.0, 3.0 Hz, 1H), 2.57 – 2.45 (m, 1H), 2.00 
(ddd, J = 11.5, 7.5, 3.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 
171.8, 154.2, 140.1, 139.0, 136.9, 129.2, 128.9, 128.5, 128.3, 
127.3, 126.4, 123.9, 123.1, 122.7, 121.4, 117.9, 115.1, 79.9, 65.2, 
56.5, 49.2, 36.7; HRMS [APCI+]: m/z calcd. for C24H21N2O 
353.1648, found 353.1644 [M+H]+. 
 
4.3.7. (±)-(10bR,11R)-5-Benzyl-10b-(2-hydroxyethyl)-11-
methyl-10b,11-dihydro-5H-indolo[2,3b]quinolin- 11-ol (19)  
 
To a solution of 137 (360 mg, 0.977 mmol) in THF (12 mL) at 0 
°C was added methylmagnesium bromide (3M in THF, 0.72 mL, 
2.150 mmol). The mixture was stirred for 10 minutes before the 
ice-bath was removed and stirring continued for a further 1h at rt. 
NH4Cl (aq.) (10 ml) was added and the organic solvent was 
removed under reduced pressure before the mixture was 
extracted with DCM (3 x 10 ml). The combined organic extracts 
were dried (MgSO4), filtered and concentrated to give the crude 
product. The crude product was purified by column 
chromatography (EtOAc/hexanes) to give 19 as a yellow solid 
(367 mg, 98%). m.p. 114-117 °C; I.R. (KBr) νmax: 2921, 2852, 
1552, 1467, 1452, 1204, 754, 700 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.64 (dd, J = 7.5, 1.5 Hz, 1H), 7.52 (dt, J = 6.5, 0.5 Hz, 
1H), 7.38 – 7.21 (m, 7H), 7.16 (ddd, J = 8.0, 7.5, 1.5 Hz, 1H), 
7.10 – 7.02 (m, 2H), 6.89 (dd, J = 8.0, 1.0 Hz, 1H), 5.70 (d, J = 
16.5 Hz, 1H), 5.01 (d, J = 16.5 Hz, 1H), 3.68 (ddd, J = 11.5, 9.5, 
3.5 Hz, 1H), 3.53 (dt, J = 11.5, 4.5 Hz, 1H), 2.39 (ddd, J = 14.5, 
9.5, 4.5 Hz, 1H), 1.71 (ddd, J = 14.5, 5.0, 3.5 Hz, 1H), 1.17 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 175.6, 155.9, 138.3, 137.0, 
135.6, 132.6, 128.8, 128.7, 128.4, 127.3, 126.6, 124.7, 123.8, 
123.6, 122.4, 117.8, 114.8, 74.3, 60.1, 59.2, 49.1, 35.2, 25.7; 
HRMS [ES+]: m/z calcd. for C25H24N2O2Na 407.1735, found 
407.1743 [M+Na]+. 
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4.3.8 (±)-(10bR,11R)-5-Benzyl-11-ethyl-10b-(2-hydroxy-
ethyl)-10b,11-dihydro-5H-indolo[2,3-b]quinolin- 11-ol (20) 
 
To a solution of 137 (160 mg, 0.434 mmol) in THF (16 mL) at 0 
°C was added ethylmagnesium bromide (3M in THF, 0.58 mL, 
1.74 mmol). The mixture was stirred for 10 minutes before the 
ice-bath was removed and stirring continued for a further 1h at rt. 
NH4Cl (aq.) (15 ml) was added and the organic solvent was 
removed under reduced pressure before the mixture was 
extracted with DCM (3 x 15 ml). The combined organic extracts 
were dried (MgSO4), filtered and concentrated to give the crude 
product. The crude product was purified by column 
chromatography (EtOAc/hexanes) to give 20 as a white solid 
(166 mg, 96%). m.p. 115-117 °C; I.R. (KBr) νmax: 3232, 3054, 
2921, 1555, 1469, 1452, 1209, 751 cm-1. 1H NMR (500 MHz, 
CDCl3) δ 7.54 (dd, J = 7.5, 1.0 Hz, 1H), 7.48 (d, J = 7.5 Hz, 1H), 
7.37 – 7.17 (m, 8H), 7.13 – 7.03 (m, 2H), 6.95 (d, J = 7.5 Hz, 
1H), 5.73 (d, J = 16.5 Hz, 1H), 5.07 (d, J = 15.5 Hz, 1H), 4.57 (s, 
1H), 3.68 – 3.58 (m, 1H), 3.51 – 3.44 (m, 1H), 2.40 (ddd, J = 
14.5, 9.0, 4.0 Hz, 1H), 1.77 – 1.69 (m, 1H), 1.50 (dq, J = 14.5, 
7.5 Hz, 1H), 1.42 (dq, J = 12.0, 6.0, 5.0 Hz, 1H), 0.58 (t, J = 7.5 
Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 175.0, 154.8, 138.1, 
136.5, 134.7, 130.0, 128.8, 128.5, 127.5, 126.8, 126.7, 124.0, 
123.4, 122.9, 117.4, 115.4, 76.3, 60.6, 58.8, 49.7, 35.3, 28.6, 7.6; 
HRMS [ES+]: m/z calcd. for C26H26N2O2Na 421.1892, found 
421.1892 [M+H]+. 
 
4.3.9. (±)-(10bR,11R)-11-Allyl-5-benzyl-10b-(2-hydroxy-
ethyl)-10b,11-dihydro-5H-indolo[2,3-b]quinolin- 11-ol (21) 
 
To a solution of 137 (2.65 g, 7.20 mmol) in THF (100 mL) at 0 
°C was added allylmagnesium bromide (2M in THF, 10.8 mL, 
21.61 mmol). The mixture was stirred for 10 minutes before the 
ice-bath was removed and stirring continued for a further 1h at rt. 
NH4Cl (aq.) (100 ml) was added and the organic solvent was 
removed under reduced pressure before the mixture was 
extracted with DCM (3 x 100 ml). The combined organic extracts 
were dried (MgSO4), filtered and concentrated to give the crude 
product. The crude product was purified by column 
chromatography (EtOAc/hexanes) to give 21 as a pale yellow 
solid (2.72 g, 92%). m.p. 88-91 °C; I.R. (KBr) νmax: 3069, 2926, 
2852, 1553, 1467, 1452, 1214, 1108, 737, 700, 503 cm-1. 1H 
NMR (400 MHz, CDCl3) δ 7.53 (dt, J = 7.5, 1.0 Hz, 1H), 7.46 
(dd, J = 7.5, 1.5 Hz, 1H), 7.40 – 7.25 (m, 7H), 7.20 (ddd, J = 8.0, 
7.5, 1.5 Hz, 1H), 7.08 (tdd, J = 7.5, 2.5, 1.5 Hz, 2H), 6.94 (dd, J 
= 8.0, 1.0 Hz, 1H), 5.69 (d, J = 16.5 Hz, 1H), 5.45 (dddd, J = 
16.5, 10.0, 8.0, 6.5 Hz, 1H), 5.07 (d, J = 16.5 Hz, 1H), 4.98 (ddt, 
J = 10.0, 2.0, 1.0 Hz, 1H), 4.85 – 4.78 (m, 1H), 4.39 (s, 1H), 3.60 
(d, J = 10.0 Hz, 1H), 3.47 (d, J = 7.0 Hz, 1H), 2.51 – 2.38 (m, 
1H), 2.31 – 2.17 (m, 2H), 1.79 (ddd, J = 14.5, 5.5, 4.0 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 175.2, 155.8, 138.4, 136.8, 135.4, 
132.6, 129.9, 128.8, 128.5, 127.4, 126.7, 126.4, 124.0, 123.0, 
122.6, 119.5, 117.8, 115.0, 75.6, 60.0, 59.0, 49.2, 41.0, 35.2; 
HRMS [APCI+]: m/z calcd. for C27H26N2O2 410.1989, found 
410.1983 [M]+.  
 
4.3.10. (±)-(3aR,13bR)-9-Benzyl-13b-methyl-2,3,9,13b-
tetrahydrofuro[3,2-c]indolo[2,3-b]quinoline (16) 
 
To a solution of 19 (367 mg, 0.955 mmol) in pyridine (10 mL) 
was added p-toluenesulfonyl chloride (113 mg, 1.145 mmol) and 
the solution stirred at rt for 2h. The mixture was then heated to 60 
°C for a further 5h before cooling to room temperature and 
adding 1M HCl (150 mL). The mixture was extracted with DCM 
(3 x 60 mL) and the combined organic extracts were dried 
(MgSO4), filtered and concentrated to give the crude product. 
Purification by column chromatography (EtOAc/hexanes) gave 
16 as a pale yellow solid (282 mg, 81%). m.p 158- 160 °C; I.R. 
(KBr) νmax: 2921, 1552, 1469, 1449, 1204, 1120, 751 cm-1. 1H 
NMR (400 MHz, CDCl3) δ 7.50 (dd, J = 7.5, 1.5 Hz, 1H), 7.31 – 
7.15 (m, 9H), 7.10 – 7.05 (m, 1H), 7.01 – 6.95 (m, 2H), 6.80 (dd, 
J = 8.0, 1.0 Hz, 1H), 5.74 (d, J = 16.5 Hz, 1H), 5.01 (d, J = 16.5 
Hz, 1H), 4.20 (q, J = 8.5 Hz, 1H), 3.81 (ddd, J = 10.0, 8.5, 3.5 
Hz, 1H), 2.61 (ddd, J = 12.5, 10.0, 8.0 Hz, 1H), 2.07 (ddd, J = 
12.0, 8.0, 3.5 Hz, 1H), 1.23 (s, 3H); 13C NMR (101 MHz, CDCl3) 
δ 172.1, 154.7, 138.2, 138.1, 136.9, 129.3, 128.8, 128.4, 127.3, 
126.7, 126.4, 123.3, 122.7, 122.3, 117.9, 114.9, 84.9, 64.6, 60.1, 
49.0, 37.2, 22.7; HRMS [ES+]: m/z calcd. for C25H23N2O 
367.1810, found 367.1803 [M+H]+. 
 
4.3.11. (±)-(3aR,13bR)-9-Benzyl-13b-ethyl-2,3,9,13b-tetrahydro-
furo[3,2-c]indolo[2,3-b]quinoline (17) 
 
To a solution of 20 (50 mg, 0.125 mmol) in pyridine (2 mL) was 
added p-toluenesulfonyl chloride (26 mg, 0.138 mmol) and the 
solution stirred at rt for 2h. The mixture was then heated to 60 °C 
for a further 5 hours before cooling to rt and adding 1M HCl (30 
mL). The mixture was extracted with DCM (3 x 15 mL) and the 
combined organic extracts were dried (MgSO4), filtered and 
concentrated to give the crude product. Purification by column 
chromatography (EtOAc/hexanes) gave 17 as a white solid (40 
mg, 84%). m.p. 177-180 °C; I.R. (KBr) νmax: 2921, 1552, 1467, 
1452, 1204, 1098, 1024, 798, 759 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 7.46 (dd, J = 7.5, 1.5 Hz, 1H), 7.33 – 7.15 (m, 8H), 
7.11 (ddd, J = 8.0, 7.5, 1.5 Hz, 1H), 7.03 – 6.96 (m, 2H), 6.84 
(dd, J = 8.0, 1.0 Hz, 1H), 5.78 (d, J = 16.5 Hz, 1H), 4.94 (d, J = 
16.5 Hz, 1H), 4.17 (q, J = 8.5 Hz, 1H), 3.79 (ddd, J = 10.0, 8.5, 
3.5 Hz, 1H), 2.59 (ddd, J = 12.5, 10.0, 8.5 Hz, 1H), 2.03 (ddd, J 
= 12.5, 8.0, 3.5 Hz, 1H), 1.84 – 1.66 (m, 2H), 0.38 (t, J = 7.6 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 172.9, 154.6, 139.5, 137.8, 
137.0, 128.9, 128.8, 128.3, 127.4, 127.3, 127.3, 126.5, 123.1, 
122.6, 122.4, 118.1, 114.7, 87.6, 64.4, 59.2, 49.2, 38.3, 30.1, 7.9; 
HRMS [ES+]: m/z calcd. for C26H25N2O 381.1967, found 
381.1967 [M+H]+.  
 
4.3.12. (±)-(3aR,13bR)-13b-Allyl-9-benzyl-2,3,9,13b-
tetrahydrofuro[3,2-c]indolo[2,3-b]quinoline (18) 
 
To a solution of 21 (1.00 g, 2.436 mmol) in pyridine (25 mL) was 
added p-toluenesulfonyl chloride (0.56 g, 2.923 mmol) and the 
solution stirred at rt for 2h. The mixture was then heated to 60 °C 
for a further 5h before cooling to rt and adding 1M HCl (320 
mL). The mixture was extracted with DCM (4 x 150 mL) and the 
combined organic extracts were dried (MgSO4), filtered and 
concentrated to give the crude product. Purification by column 
chromatography (EtOAc/hexanes) gave 18 as a yellow solid 
(0.67 g, 70%). m.p. 48-51 °C; I.R. (KBr) νmax: 2926, 1555, 1467, 
1452, 1327, 1295, 1204, 919, 751, 700 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.46 (dd, J = 7.5, 1.5 Hz, 1H), 7.34 – 7.14 (m, 8H), 
7.09 (ddd, J = 8.0, 7.5, 1.5 Hz, 1H), 6.99 (tdd, J = 7.5, 4.0, 1.0 
Hz, 2H), 6.81 (dd, J = 8.0, 1.0 Hz, 1H), 5.68 (d, J = 16.5 Hz, 1H), 
5.18 – 5.03 (m, 1H), 4.97 (d, J = 16.5 Hz, 1H), 4.64 (ddt, J = 
10.0, 2.0, 1.0 Hz, 1H), 4.37 (dq, J = 17.0, 1.5 Hz, 1H), 4.18 (q, J 
= 8.5 Hz, 1H), 3.80 (ddd, J = 10.0, 8.5, 3.5 Hz, 1H), 2.64 – 2.51 
(m, 1H), 2.51 – 2.39 (m, 2H), 2.03 (ddd, J = 12.5, 8.0, 3.5 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 172.5, 154.8, 139.3, 137.7, 
136.9, 130.9, 129.0, 128.8, 128.4, 127.4, 127.3, 127.1, 126.6, 
123.1, 122.6, 122.3, 119.4, 118.1, 114.7, 86.1, 64.4, 59.2, 49.2, 
41.7, 38.0. HRMS [ES+]: m/z calcd. for C27H25N2O 393.1961, 
found 393.1959 [M+H]+. 
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ACCEPTED MANUSCRIPT4.3.13. (±)-2-((2'R,10bR)-5-Benzyl-5,10b-dihydrospiro-
[indolo[2,3-b]quinoline-11,2'-oxirane]-10b-yl) ethanol (24) 
 
To a solution of 23 (500 mg, 0.805 mmol) in THF (25 mL) was 
added TBAF (1 M in THF, 1.6 mL, 1.611 mmol) and the mixture 
stirred at rt for 2h. NH4Cl (aq.) (25 mL) was added and the 
organic solvent was removed under reduced pressure before the 
mixture was extracted with DCM (3 x 20 mL). The combined 
organic extracts were dried (MgSO4), filtered and concentrated to 
give the crude product which was purified by column 
chromatography (EtOAc/hexanes) to give 24 as a yellow-orange 
solid (302 mg, 98%). m.p. 86-88 °C; I.R. (KBr) νmax: 2921, 1671, 
1607, 1555, 1489, 1452, 1403, 1204, 1027, 909, 754, 729, 697 
cm
-1; 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.11 (m, 10H), 7.00 – 
6.94 (m, 2H), 6.87 (dd, J = 8.0, 1.0 Hz, 1H), 5.76 (d, J = 16.5 Hz, 
1H), 4.94 (d, J = 16.5 Hz, 1H), 3.44 – 3.27 (m, 2H), 3.05 (d, J = 
5.5 Hz, 1H), 2.52 (d, J = 5.5 Hz, 1H), 2.36 (dt, J = 13.5, 6.5 Hz, 
1H), 2.10 (dt, J = 14.0, 6.5 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 173.0, 155.1, 140.9, 136.6, 133.8, 129.5, 129.2, 128.9, 
127.4, 126.4, 123.7, 123.5, 123.0, 122.9, 118.3, 115.2, 60.2, 59.1, 
54.1, 53.6, 49.7, 36.6; HRMS [ES+]: m/z calcd. for C25H23N2O2 
383.1760, found 383.1745 [M+H]+. 
 
4.3.14. (±)-((3aR,13bR)-9-Benzyl-2,3,9,13b-tetrahydrofuro-
[3,2-c]indolo[2,3-b]quinolin-13b-yl)methanol (25) 
 
To a solution of 24 (1.20 g, 3.138 mmol) in DCM (70 mL) was 
added p-toluenesulfonic acid (1.62 g, 9.413 mmol) and the 
mixture stirred at rt for 18h. NaHCO3 (aq.) (70 mL) was added 
and the mixture extracted with DCM (3 x 50 mL) before the 
combined organic extracts were dried (MgSO4), filtered and 
concentrated. The crude product which was purified by column 
chromatography (EtOAc/hexanes) to give 25 as a yellow-orange 
solid (1.13 g, 94%). m.p. 151-155 °C; I.R. (KBr) νmax: 3320, 
2921, 1555, 1491, 1469, 1452, 1413, 1324, 1206, 1147, 1064, 
756, 692 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.55 (dd, J = 7.5, 
1.5 Hz, 1H), 7.46 (dt, J = 7.5, 1.0 Hz, 1H), 7.31 – 7.14 (m, 8H), 
7.09 – 6.96 (m, 2H), 6.88 (dd, J = 8.0, 1.0 Hz, 1H), 5.66 (d, J = 
16.5 Hz, 1H), 5.31 (br. s, 1H), 4.89 (d, J = 16.5 Hz, 1H), 3.55 
(ddd, J = 11.0, 9.0, 3.5 Hz, 1H), 3.49 – 3.34 (m, 3H), 2.42 (ddd, J 
= 14.5, 9.0, 4.5 Hz, 1H), 1.66 (ddd, J = 14.5, 5.0, 3.5 Hz, 1H); 
13C NMR (75 MHz, CDCl3) δ 174.4, 155.6, 138.7, 136.7, 134.1, 
129.4, 129.2, 128.9, 127.9, 127.5, 127.3, 126.5, 124.2, 123.1, 
122.8, 118.1, 115.0, 75.2, 59.1, 58.6, 50.1, 49.4, 35.9; HRMS 
[ES+]: m/z calcd. for C25H23N2O2 383.1760, found 383.1765 
[M+H]+. 
 
4.3.15. (±)-2-((10bR,11S)-5-Benzyl-11-(p-tolyl)-10b,11-
dihydro-5H-indolo[2,3-b]quinolin-10b-yl)ethanol (26) 
 
26 was synthesised from the reaction of 14 (40 mg, 0.113 mmol) 
with AlCl3 (106 mg, 0.794 mmol) in toluene (3 mL) using 
general procedure 4.2.1. 26 was obtained as a pale yellow solid 
(39 mg, 77%). m.p. 63-65 °C; I.R. (KBr) νmax: 2921, 2852, 1555, 
1469, 1454, 1078, 776, 692, 459 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.52 – 7.47 (m, 2H), 7.39 – 7.33 (m, 2H), 7.32 – 7.07 
(m, 7H), 7.01 – 6.92 (m, 2H), 6.79 – 6.71 (m, 4H), 5.86 (d, J = 
16.5 Hz, 1H), 5.16 (d, J = 16.5 Hz, 1H), 4.46 (s, 1H), 3.38 – 3.26 
(m, 2H), 2.36 (dt, J = 13.5, 6.5 Hz, 1H), 2.26 – 2.17 (m, 1H), 
2.10 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 172.5, 153.8, 139.4, 
136.6, 136.4, 135.5, 135.5, 135.4, 130.5, 128.8, 128.4, 127.8, 
127.6, 127.3, 126.4, 123.9, 122.8, 122.4, 117.3, 115.9, 59.1, 56.2, 
50.8, 50.1, 39.8, 20.9; HRMS [ES+]: m/z calcd. for C31H29N2O 
445.2280, found 445.2275 [M+H]+. 
 
4.3.16. (±)-2-((10bR,11S)-5-Benzyl-11-methyl-11-(p-tolyl)-
10b,11-dihydro-5H-indolo[2,3-b]quinolin-10b-yl)ethanol (27) 
 
27 was synthesised from the reaction of 16 (29 mg, 0.079 mmol) 
with AlCl3 (74 mg, 0.552 mmol) in toluene (1.5 mL) using 
general procedure 4.2.1. 27 was obtained as a pale yellow solid 
(30 mg, 83%). m.p. 108- 111 °C; I.R. (KBr) νmax: 3374, 2956, 
2916, 1555, 1491, 1449, 1408, 1245, 1211, 1027, 835, 751, 697 
cm
-1; 1H NMR (300 MHz, CDCl3) δ 7.63 – 7.51 (m, 1H), 7.37 – 
7.15 (m, 8H), 7.14 – 7.02 (m, 4H), 6.75 – 6.64 (m, 2H), 6.54 – 
6.41 (m, 2H,), 5.48 (d, J = 16.5 Hz, 1H), 5.01 (d, J = 16.5 Hz, 
1H), 3.23 (dt, J = 11.0, 7.0 Hz, 1H), 3.03 (dt, J = 11.0, 6.5 Hz, 
1H), 2.29 (t, J = 7.0 Hz, 2H), 2.13 (s, 3H), 2.09 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 173.4, 156.0, 141.3, 139.2, 137.2, 136.5, 
136.0, 131.2, 128.6, 128.6, 128.3, 128.0, 127.3, 127.3, 126.9, 
123.6, 123.0, 122.4, 117.7, 115.3, 59.6, 58.6, 50.1, 47.4, 35.6, 
22.3, 20.8; HRMS [ES+]: m/z calcd. for C32H30N2ONa 
481.2256, found 481.2247 [M+Na]+. 
 
4.3.17. (±)-2-((10bR,11S)-5-Benzyl-11-ethyl-11-(p-tolyl)-
10b,11-dihydro-5H-indolo[2,3-b]quinolin-10b-yl)ethanol (28) 
 
28 was synthesised from the reaction of 17 (30 mg, 0.079 mmol) 
with AlCl3 (74 mg, 0.552 mmol) in toluene (1.5 mL) using 
general procedure 4.2.1. 17 was obtained as a pale yellow solid 
(26 mg, 70%). m.p. 140- 143 °C; I.R. (KBr) νmax: 3261, 2921, 
1555, 1449, 1407, 1209, 1019, 751, 727 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.61 – 7.53 (m, 1H), 7.53 – 7.44 (m, 1H), 7.39 – 
6.98 (m, 11H), 6.77 – 6.65 (m, 2H), 6.42 – 6.30 (m, 2H), 5.33 (d, 
J = 16.5 Hz, 1H), 4.94 (d, J = 16.5 Hz, 1H), 3.18 (dt, J = 11.0, 
7.0 Hz, 1H), 3.04 (dt, J = 11.0, 6.5 Hz, 1H), 2.75 (dq, J = 15.0, 
7.5 Hz, 1H,), 2.63 (dq, J = 14.0, 7.0 Hz, 1H), 2.28 (dd, J = 8.0, 
6.0 Hz, 2H), 2.19 (s, 3H), 0.89 (t, J = 7.0 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 173.9, 156.3, 141.5, 137.1, 136.5, 136.0, 135.9, 
131.7, 128.8, 128.5, 128.2, 128.0, 127.3, 127.2, 127.1, 123.6, 
123.4, 122.5, 117.6, 115.8, 59.8, 59.5, 51.5, 50.2, 35.0, 26.2, 
20.9, 12.0; HRMS [ES+]: m/z calcd. for C33H33N2O 473.2593, 
found 473.2590 [M+H]+. 
 
4.3.18. (±)-2-((10bR,11S)-11-Allyl-5-benzyl-11-methyl-10b,11-
dihydro-5H-indolo[2,3-b]quinolin-10b-yl)ethanol (29) 
 
29 was synthesised from the reaction of 16 (30 mg, 0.082 mmol) 
with allyltrimethylsilane (94 mg, 0.819 mmol) and AlCl3 (76 mg, 
0.573 mmol) in DCM (0.2 mL) using general procedure 4.2.2. 29 
was obtained as a pale yellow solid (29 mg, 87%). m.p. 169-171 
°C; I.R. (KBr) νmax: 3394, 2931, 1543, 1467, 1449, 1206, 1039, 
102, 751, 705 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.46 – 7.20 
(m, 8H), 7.17 – 7.09 (m, 2H), 7.05 – 6.94 (m, 3H), 5.63 (d, J = 
16.5 Hz, 1H), 5.28 – 5.17 (m, 1H), 5.14 (d, J = 16.5 Hz, 1H), 
4.87 – 4.79 (m, 1H), 4.69 – 4.61 (m, 1H), 3.24 (dt, J = 11.0, 7.0 
Hz, 1H), 3.04 (dt, J = 11.0, 7.0 Hz, 1H), 2.21 – 2.07 (m, 3H), 
1.81 (dd, J = 13.5, 9.0 Hz, 1H), 1.64 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 174.5, 156.7, 139.8, 137.5, 136.4, 134.1, 130.1, 129.2, 
129.1, 128.2, 127.8, 127.7, 127.4, 123.4, 123.2, 122.9, 118.5, 
118.1, 115.9, 59.7, 58.6, 50.0, 43.2, 40.4, 35.1, 18.5; HRMS 
[APCI+]: m/z calcd. for C28H28N2O 408.2196, found 408.2192 
[M]+. 
 
4.3.19. (±)-2-((10bR,11S)-11-Allyl-5-benzyl-11-ethyl-10b,11-
dihydro-5H-indolo[2,3-b]quinolin-10b-yl)ethanol (30) 
 
30 was synthesised from the reaction of 17 (20 mg, 0.053 mmol) 
with allyltrimethylsilane (60 mg, 0.526 mmol) and AlCl3 (49 mg, 
0.368 mmol) in DCM (0.15 mL) using general procedure 3. 30 
was obtained as a pale yellow solid (15 mg, 68%). m.p. 65-67 °C; 
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I.R. (KBr) νmax: 3411, 3063, 2923, 1701, 1554, 1491, 1467, 
1450, 1205, 1041, 836, 754, 698 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 7.41 – 7.21 (m, 10H), 7.19 – 7.13 (m, 2H), 7.07 – 6.99 
(m, 3H), 5.61 (d, J = 16.5 Hz, 1H), 5.19 – 5.09 (m, 2H), 4.72 (dt, 
J = 10.0, 1.5 Hz, 1H), 4.62 – 4.54 (m, 1H), 3.23 (dq, J = 11.0, 
7.0, 6.5 Hz, 1H), 3.01 (ddd, J = 11.0, 7.5, 6.0 Hz, 1H), 2.40 (dq, J 
= 15.5, 7.5 Hz, 1H), 2.29 – 2.13 (m, 4H), 1.87 (dd, J = 14.5, 8.5 
Hz, 1H), 1.34 (t, J = 7.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 
174.0, 155.9, 140.0, 136.8, 136.1, 134.2, 128.8, 128.7, 128.4, 
128.0, 127.7, 127.3, 127.1, 123.1, 122.8, 122.7, 117.5, 117.5, 
116.0, 59.4, 59.1, 49.8, 45.9, 40.4, 35.9, 25.8, 11.8; LRMS 
[ES+]: m/z calcd. for C29H31N2O 423.24, found 423.39 [M+H]+. 
 
4.3.20. (±)-2-(11,11-Diallyl-5-benzyl-10b,11-dihydro-5H-
indolo[2,3-b]quinolin-10b-yl)ethanol (31) 
 
To a solution of 18 (663 mg, 1.689 mmol) in DCM (14 mL) at -
78 °C was added allyltrimethylsilane (1.34 mL, 8.446 mmol) 
followed by TiCl4 (dropwise addition, 0.93 mL, 8.446 mmol). 
The mixture was stirred at -78 °C for 4.5h before methanol (1 
mL) was added and the mixture stirred for an additional 10 
minutes. The mixture was removed from the cold bath and 
NH4Cl (aq.) (15 mL) was added before the mixture was extracted 
with DCM (3 x 10 mL). The combined organic extracts were 
dried (MgSO4), filtered and concentrated before the crude 
product was purified by column chromatography 
(EtOAc/hexanes) to give 31 as a yellow solid (636 mg, 87%). 
m.p. 116- 118 °C; I.R. (KBr) νmax: 3355, 2931, 1641, 1469, 919, 
759, 732 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.36 (m, 
3H), 7.34 – 7.14 (m, 7H), 7.08 – 6.98 (m, 3H), 6.23 (dtd, J = 
17.0, 10.0, 4.0 Hz, 1H), 5.61 (d, J = 16.5 Hz, 1H), 5.39 (d, J = 
17.0 Hz, 1H), 5.21 – 5.08 (m, 3H), 4.81 (d, J = 10.0 Hz, 1H), 
4.65 (d, J = 17.0 Hz, 1H), 3.26 – 3.12 (m, 2H), 2.99 – 2.81 (m, 
2H), 2.46 (ddd, J = 13.5, 8.0, 6.0 Hz, 1H), 2.21 (dd, J = 14.0, 6.0 
Hz, 1H), 2.10 (tdd, J = 14.5, 9.5, 6.0 Hz, 1H), 1.84 (dd, J = 14.0, 
9.0 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 174.1, 157.3, 140.4, 
137.3, 137.1, 136.4, 134.1, 129.2, 129.1, 128.5, 128.3, 128.0, 
127.7, 127.5, 123.7, 123.1, 118.7, 118.0, 116.7, 116.4, 59.8, 59.6, 
50.1, 46.3, 40.8, 37.9, 36.2; HRMS [ES+]: m/z calcd. for 
C30H31N2O 435.2431, found 435.2430 [M+H]+. 
 
4.3.21. (±)-(6aR,9aR,13aR,14R,15aS)-15a-Allyl-5-benzyl-
10,12-diiodo-14-(iodomethyl)-7,8,9a,14,15,15a-hexahydro-5H-
6,13-(azeno)chromeno[4',4a':1,5]cyclopenta[1,2-c]quinoline 
(33) and (±)-(6aR,9aS,13aR,14R,15aS)-15a-Allyl-5-benzyl-14-
(iodomethyl)-7,8,9a,14,15,15a-hexahydro-5H- 6,13-(azeno)-
chromeno[4',4a':1,5]cyclopenta[1,2-c]quinoline (34) 
 
To a solution of 31 (50 mg, 0.115 mmol) in DCM (2.3 mL) was 
added NIS (31 mg, 0.138 mmol) and the mixture stirred at rt for 
1h. Na2S2O3 (aq.) (2 mL) was added and the mixture stirred for a 
further 10 minutes before being extracted with DCM (3 x 2mL). 
The combined organic extracts were dried (MgSO4), filtered and 
concentrated before purification by column chromatography 
(EtOAc/hexanes) giving a mixture of products including 
recovered 31 (20 mg, 40%). 33  was obtained as a yellow solid 
(14 mg, 15%). m.p. 150-152 °C; I.R. (KBr) νmax: 2921, 1567, 
1520, 1494, 1462, 1327, 1211, 1076, 744 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.54 (dd, J = 8.0, 1.0 Hz, 1H), 7.38 – 7.25 (m, 
5H), 7.20 (t, J = 8.0 Hz, 1H), 7.11 – 7.01 (m, 3H), 6.12 – 6.00 
(m, 1H), 5.74 (d, J = 16.0 Hz, 1H), 5.34 (d, J = 17.0 Hz, 1H), 
5.27 (d, J = 10.5 Hz, 1H), 5.00 (d, J = 16.0 Hz, 1H), 4.27 (s, 1H), 
4.05 (dd, J = 12.0, 5.5 Hz, 1H), 3.72 (td, J = 12.5, 2.5 Hz, 1H), 
3.44 (dd, J = 9.5, 3.5 Hz, 1H), 2.93 – 2.83 (m, 2H), 2.73 (dd, J = 
11.5, 9.5 Hz, 1H), 2.56 – 2.42 (m, 2H), 1.77 – 1.71 (m, 1H), 1.68 
– 1.59 (m, 1H), 1.41 – 1.33 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 174.4, 157.4, 146.5, 137.6, 136.4, 134.2, 129.6, 128.9, 
128.6, 128.2, 127.7, 127.2, 123.4, 118.7, 116.3, 88.0, 82.9, 67.2, 
66.5, 60.1, 57.4, 50.2, 48.3, 45.7, 44.7, 39.2, 27.5, 9.0; HRMS 
[ES+]: m/z calcd. for C30H28I3N2O 812.9330, found 812.9329 
[M+H]+. 34 was obtained as a green solid (6 mg, 9%). m.p. 126-
128 °C (dec.); I.R. (KBr) νmax: 2921, 1722, 1639, 1533, 1491, 
1459, 1410, 1327, 1073, 914, 729 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 7.56 (dd, J = 8.0, 1.5 Hz, 1H), 7.36 – 7.29 (m, 2H), 
7.29 – 7.23 (m, 3H), 7.19 – 7.13 (m, 1H), 7.01 (t, J = 7.5 Hz, 
1H), 6.96 (d, J = 8.0 Hz, 1H), 6.38 (dd, J = 9.5, 5.5 Hz, 1H), 6.13 
(ddt, J = 17.0, 10.0, 6.5 Hz, 1H), 5.91 (d, J = 5.5 Hz, 1H, C12-
H), 5.82 – 5.72 (m, 2H, CH2N, C10-H), 5.33 (d, J = 17.0 Hz, 
1H), 5.26 (d, J = 10.0 Hz, 1H), 4.87 (d, J = 16.0 Hz, 1H), 4.15 (d, 
J = 6.0 Hz, 1H), 4.01 (dd, J = 12.0, 6.0 Hz, 1H), 3.78 (td, J = 
12.5, 2.5 Hz, 1H), 3.45 (dd, J = 9.5, 3.5 Hz, 1H), 3.04 (dd, J = 
16.0, 6.5 Hz, 1H), 2.95 (dd, J = 16.0, 6.5 Hz, 1H), 2.86 (dd, J = 
12.0, 9.5 Hz, 1H), 2.56 (dd, J = 13.5, 6.5 Hz, 1H), 2.50 – 2.40 
(m, 1H), 1.83 – 1.77 (m, 1H), 1.71 – 1.63 (m, 1H), 1.50 – 1.41 
(m, 1H); 13C NMR (126 MHz, CDCl3) δ 174.3, 155.4, 138.3, 
136.7, 134.7, 131.8, 129.7, 128.9, 128.5, 128.0, 127.4, 126.4, 
122.7, 118.3, 116.7, 115.7, 105.6, 77.4, 67.0, 57.3, 53.4, 49.9, 
48.3, 45.4, 44.7, 39.6, 28.0, 10.7; LRMS [ES+]: m/z calcd. for 
C30H29IN2O 561.14, found 561.02 [M+H]+.  
 
4.3.22. (±)-(6aR,9aR,13aR,14R,15aS)-15a-Allyl-5-benzyl-
10,12-diiodo-14-(iodomethyl)-7,8,9a,14,15,15a-hexahydro-5H-
6,13-(azeno)chromeno[4',4a':1,5]cyclopenta[1,2-c]quinoline 
(33) 
 
To a solution of 31 (50 mg, 0.115 mmol) in DCM (2.3 mL) was 
added NIS (93 mg, 0.414 mmol) and the mixture stirred at rt for 
1h. Na2S2O3 (aq.) (2 mL) was added and the mixture stirred for a 
further 10 minutes before being extracted with DCM (3 x 2 mL). 
The combined organic extracts were dried (MgSO4), filtered and 
concentrated before purification by column chromatography 
(EtOAc/hexanes) giving 33 as a yellow solid (60 mg, 64%). All 
characterisation data were in agreement with that reported above 
for 33. Crystals suitable for X-ray crystallographic analysis were 
obtained by the slow evaporation of a solution of 33 in 
EtOAc/MeOH.  
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Supplementary Material 
Crystallographic data (excluding structure factors) for the 
structures in this paper have been deposited with the Cambridge 
Crystallographic Data Centre as supplementary publication 
numbers CCDC 1811883 (6); CCDC 1811882 (7); CCDC 
1811884 (33).  
Additional results and discussion of supplementary 
compounds are discussed in the ESI. 
 
 
